Back to Newsroom

Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine

Zug, Switzerland, February 7, 2018 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today reported new data on the pharmacokinetics of AM-125, its investigational drug for the intranasal treatment of vertigo.